Loading
FS-207 is an experimental oral small molecule from Fushi Biotechnology, in phase 1 trials for MSI-high advanced solid tumours.
FS-207 is an oral small molecule (tablet) from Fushi Biotechnology. Targets the WRN helicase; developed for solid tumours with high microsatellite instability (MSI-H). Its furthest stage is phase 1, for MSI-high advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. NMPA implied clinical trial approval April 2026 (company news); phase 1a/1b NCT07593144 not yet recruiting. Whether it works in people has not been established unless a trial below reports it.
Targets the WRN helicase; developed for solid tumours with high microsatellite instability (MSI-H). Connects to WRN helicase (MSI-high cancers).
1.FS-207 slips into a pocket on WRN helicase (MSI-high cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FS-207" OR ABSTRACT:"FS-207") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FS-207, not a curated reading list.
Shares Fushi Biotechnology, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares WRN helicase (MSI-high cancers), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares WRN helicase (MSI-high cancers) and the tag pipeline.
Shares WRN helicase (MSI-high cancers) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/